A Study about Blood Pressure Management in Patients with Primary Aldosteronism
Official TitleA Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Effectiveness of CIN-107 for the Management of Blood Pressure in Patients with Primary Aldosteronism
The purpose of this study is to see how the study drug CIN-107 works in managing blood pressure in patients with primary aldosteronism (PA), a hormone disorder which causes your body to produce too much of the hormone aldosterone.
The duration of this study is 74 weeks.
Could this study be right for you?
- Diagnosis of primary aldosteronism (PA)
- Taking an MRA to control BP, such as Spironolactone or Eplerenone, or not yet taking an MRA
18 and up